Provided by Tiger Trade Technology Pte. Ltd.

Credit Suisse Holdings

2,430.33
+24.701.03%
Number of Gainers:81
Number of Losers:16
Number of Flat:- -
PE:- -
High:2,440.43
Open:2,406.04
Low:2,406.04
Close:2,405.63
Volume:1.18B
Turnover:257.13B
Market Cap:50.95T
Float Cap:47.62T

Loading ...

ADP Expands Strategic Partnership with AWS to Accelerate AI-Powered HCM Innovation

Reuters
·
Sep 08

Verizon, Corning enter multi-billion dollar agreement for 80M miles of fiber

TIPRANKS
·
Sep 08

Malaysia's Maybank Raises $700 Million in Dual-Tranche Dollar Bond Sale, Term Sheet Shows

Reuters
·
Sep 08

Qualcomm Stock Jumps 8% Thanks to Deal with Amazon

Dow Jones
·
Sep 08

Autodesk, Inc.: Files for Two-Part Notes Offering, Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 08

Qualcomm to issue warrant to Amazon.com for up to 25M shares

TIPRANKS
·
Sep 08

Amazon and AT&T Team up to Challenge SpaceX's Satellite Dominance

Dow Jones
·
Sep 08

Mediacom Names Anthony Bowling Senior Vice President, Field Operations Strategy and Operational Excellence

Reuters
·
Sep 08

Accenture, Google Cloud launch Accenture Gemini Enterprise Business Group

TIPRANKS
·
Sep 08

Qualcomm Shares up 10.1% Premarket After Co, Amazon to Develop Custom Chips for AI Data Centers

THOMSON REUTERS
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Qualcomm announces multi-generation collaboration with Amazon.com

TIPRANKS
·
Sep 08

Qualcomm Partners with Amazon on Multi-Generation Custom Chips for AWS AI Data Centers

Reuters
·
Sep 08

UPS Announces R$ 0.36 Dividend Per Unit for Q3 2026

Reuters
·
Sep 08

LIVE Markets-the Factor Derby is Down to Two Horses

Reuters
·
Sep 08

Notable open interest changes for September 8th

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08